相关实验视频

Updated: Jul 18, 2025

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

在恶性瘤中 lncRNA BBOX1-AS1 的预后效应:一个元分析

Guangyao Lin¹, Yongzhou Wang², Li Deng²

¹Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Frontiers in genetics

|August 28, 2023

概括

高表达的BBOX1反感官RNA1 (BBOX1-AS1) 与较差的癌症存活率和晚期疾病有关. 这种长长的非编码RNA可以作为预测癌症预后和特征的有希望的生物标志物.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物标志物发现发现

背景情况:

癌症仍然是一个重大的全球健康挑战,需要有效的诊断生物标志物.
长非编码RNAs (lncRNAs) 越来越多地被认为是癌症进展中的角色.
BBOX1反感官RNA 1 (BBOX1-AS1) 是最近发现的一种 lncRNA,与各种癌症患者的不良结果有关.

研究的目的:

研究BBOX1-AS1表达水平与癌症患者临床病理参数和预后之间的关联.
评估BBOX1-AS1作为癌症预测生物标志物的潜力.

主要方法:

在六个数据库中进行了系统的文献搜索,查找到2023年4月27日发布的符合条件的研究.
使用几率比率 (OR) 和危险比率 (HR) 和95%置信区间 (CI) 进行了元分析,以评估BBOX1-AS1表达与预后和临床病理因素的关联.
通过使用GEPIA在线数据库进一步验证了结果.

主要成果:

分析了包括602名患者在内的8项研究.
高BBOX1-AS1表达显着与整体存活率差 (HR = 2.30,p < 0.00001) 相关.
升高的BBOX1-AS1表达与淋巴结转移 (OR = 3.00,p = 0.0001) 和晚期瘤阶段 (OR = 3.74,p < 0.00001) 正相关.
在12种恶性瘤中,BBOX1-AS1的调节升高,预测总体和无病生存率较差.

结论:

在各种癌症中,BBOX1-AS1与不良的整体存活率,无病存活率,淋巴结转移和瘤阶段显著相关.
BBOX1-AS1展示了作为预测癌症预后和临床病理特征的新生物标志物的潜力.

关键词:

人类的恶性瘤.在cRNA BBOX1-ASAS中.这是一个元分析.预后预后预后审查审查审查审查审查审查

更多相关视频

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

相关概念视频

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...